Voices For Life

Voices for Life is an e-publication dedicated to informing and educating the public on pro-life and pro-family issues. We cover issues from conception until natural death, as well as all family life issues.

Thursday, November 24, 2016

Controversial Sterilization Device Should be Taken Off the Market




by Jonathan Abbamonte
Population Research Institute


The U.S. Food and Drug Administration (FDA) has announced that it has approved a boxed warning for Bayer’s controversial Essure® sterilization device. A boxed warning is the strongest warning the FDA can require for drugs and devices and is intended to alert the user to potentially serious, even deadly, side effects that can result from using them.

The Essure boxed warning will alert patients and health professionals to adverse events associated with the device including the possibility for uterine perforation, chronic pain, serious allergic reactions, device migration into the abdominal or pelvic cavity, and the need for the device to be removed surgically if symptoms become unbearable.

More than 10,000 women who have suffered adverse medical events associated with Essure have already filed complaints with the FDA, and the number continues to rise daily. Nearly 5,000 women have filed complaints with the FDA this year alone. Bayer itself has received close to 30,000 additional complaints from users of its device.

The combination of the public outcry and the unusually high number of complaints led the FDA to conduct a hearing on safety issues surrounding the device last September.

Get the full story here

                 
The Population Research Institute is a (501c3) non-profit research organization whose core values hold that people are the world’s greatest resource. PRI’s goals are to educate on this premise, to expose the myth of overpopulation, and to expose human rights abuses committed in population control programs. Our growing, global network of pro-life groups spans over 30 countries.  For more information, please use this link.  



No comments:

Post a Comment